SGAM
SAGE

Smith Group Asset Management’s Sage Therapeutics SAGE Stock Holding History

Smith Group Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,160
Closed -$808K – 447
2018
Q2 		$808K Buy
5,160
+700
+16% +$110K 0.02% 184
2018
Q1 		$718K Sell
4,460
-2,380
-35% -$404K 0.02% 183
2017
Q4 		$1.13M Hold
6,840
– – 0.04% 164
2017
Q3 		$426K Hold
6,840
– – 0.01% 227
2017
Q2 		$545K Sell
6,840
-100
-1% -$7.23K 0.02% 205
2017
Q1 		$493K Sell
6,940
-10
-0.1% -$586 0.01% 185
2016
Q4 		$355K Buy
+6,950
New +$328K 0.01% 209

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Smith Group Asset Management's SAGE Position: Q3 2018 in Review

Smith Group Asset Management sold out of Sage Therapeutics (SAGE) in Q3 2018, closing a stake of 5,160 shares — an estimated $808K sold.

Smith Group Asset Management first reported a position in SAGE in Q4 2016 and held it in 7 quarters. The position peaked at $1.13M in Q4 2017. 275 funds tracked by Wall St. Rank hold SAGE as of Q3 2018.

  • Smith Group Asset Management reported no remaining Sage Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Smith Group Asset Management sold 5,160 Sage Therapeutics shares in Q3 2018, an estimated $808K.
  • Smith Group Asset Management first reported a position in Sage Therapeutics in Q4 2016 and held it in 7 quarters.
  • Smith Group Asset Management's Sage Therapeutics position peaked at $1.13M in Q4 2017.
  • 275 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2018.

Based on Smith Group Asset Management's 13F filing for Q3 2018, filed 2 Nov 2018.